Charles Craddock

Featured in: Favicon

nature.com Favicon

thelancet.com Favicon

patientpower.info Favicon

onlinelibrary.wiley.com

Articles

Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance - Leukemia

Jun 18, 2024 | nature.com | Alexandra Adams |Charles Craddock

AbstractMeasurable residual disease (MRD) surveillance in acute myeloid leukemia (AML) may identify patients destined for relapse and thus provide the option of pre-emptive therapy to improve their outcome. Whilst flow cytometric MRD (Flow-MRD) can be applied to high-risk AML/ myelodysplasia patients, its diagnostic performance for detecting impending relapse is unknown.
Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party Euro

Apr 7, 2024 | acsjournals.onlinelibrary.wiley.com | Justin Loke |Myriam Labopin |Charles Craddock |Gerard Socie

INTRODUCTION Allogeneic stem cell transplantation (SCT) plays a critical role in the management of acute myeloid leukemia (AML) in reducing the risk of disease relapse through cytotoxicity from the conditioning regimen, as well as through the graft-versus-leukemia (GVL) effect.1-3 To ensure time for this to develop, transplant strategies are premised on allografting patients in complete remission (CR).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →